Burden of lung cancer along with attributable risk factors in China from 1990 to 2019, and projections until 2030
- PMID: 35904601
- PMCID: PMC11797656
- DOI: 10.1007/s00432-022-04217-5
Burden of lung cancer along with attributable risk factors in China from 1990 to 2019, and projections until 2030
Abstract
Objective: This study aimed to identify and project the epidemiological trends and the burden of lung cancer in China.
Methods: We extracted incidence, mortality, disability-adjusted life-years (DALYs) and age-standardized rates of lung cancer in China, between 1990 and 2019, from the Global Burden of Disease Study (2019). The estimated annual percentage change (EAPC) was applied to quantify the trends of lung cancer burden. Furthermore, we used the Bayesian age-period-cohort model to project the incidence and mortality in the next decade.
Results: From 1990 to 2019, the estimated national number of lung cancer incident cases increased by 224.0% to 832,920, deaths increased by 195.4% to 757,170 and DALYs increased by 146.1% to 17,128,580, respectively. Meanwhile, the ASIR, ASMR and ASDR showed an upward trend (EAPC of 1.33, 0.94 and 0.42, respectively). The ASIR and ASMR among males were about 2 times more than females, but the increase in ASIR in females (EAPC = 2.24) was more obvious than those in males (EAPC = 0.10) from 2020 to 2030. In China, smoking remained responsible for the highest burden of lung cancer, but the contribution of ambient particulate matter pollution to DALYs increased from 10.6% in 1990 to 22.5% in 2019 in total population. Moreover, we predicted that the number of deaths from lung cancer will increase by 42.7% in China by 2030.
Conclusion: In China, the burden of lung cancer has been increasing over the past three decades, which highlights more targeted intervention measures are needed to reduce the burden of lung cancer.
Keywords: China; Lung cancer; Projections; Risk factors; Trends.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
The authors have no relevant financial or non-financial interests to disclose.
Figures




Similar articles
-
Incidence and disability-adjusted life-years of infective endocarditis in China from 1990 to 2021: comparison with G20 based on the Global Burden of Disease Study 2021.BMJ Open. 2025 Jul 6;15(7):e094490. doi: 10.1136/bmjopen-2024-094490. BMJ Open. 2025. PMID: 40623737 Free PMC article.
-
Trends and future projections of liver cancer attributable to metabolic dysfunction-associated steatohepatitis in China from 1990 to 2050.Sci Rep. 2025 Jul 2;15(1):23255. doi: 10.1038/s41598-025-06617-2. Sci Rep. 2025. PMID: 40603991 Free PMC article.
-
Global, regional, and national burden and trends of early-onset tracheal, bronchus, and lung cancer from 1990 to 2019.Thorac Cancer. 2024 Mar;15(8):601-613. doi: 10.1111/1759-7714.15227. Epub 2024 Feb 1. Thorac Cancer. 2024. PMID: 38303633 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Burden of inflammatory bowel disease among elderly, 1990-2019: A systematic analysis based on the global burden of disease study 2019.Autoimmun Rev. 2025 Jan 31;24(2):103708. doi: 10.1016/j.autrev.2024.103708. Epub 2024 Nov 23. Autoimmun Rev. 2025. PMID: 39586389
Cited by
-
Combined detection of serum IL-6 and CEA contributes to the diagnosis of lung adenocarcinoma in situ.PeerJ. 2024 Mar 22;12:e17141. doi: 10.7717/peerj.17141. eCollection 2024. PeerJ. 2024. PMID: 38529301 Free PMC article.
-
Cost-effectiveness of low-dose CT screening for non-smokers with a first-degree relative history of lung cancer.BMC Public Health. 2025 May 15;25(1):1783. doi: 10.1186/s12889-025-22977-w. BMC Public Health. 2025. PMID: 40375086 Free PMC article.
-
Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model.Front Pharmacol. 2025 Jan 24;16:1400422. doi: 10.3389/fphar.2025.1400422. eCollection 2025. Front Pharmacol. 2025. PMID: 39925845 Free PMC article.
-
Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019-2024).RSC Med Chem. 2024 Aug 30;15(10):3371-94. doi: 10.1039/d4md00384e. Online ahead of print. RSC Med Chem. 2024. PMID: 39246743 Free PMC article. Review.
-
Screening for lung cancer using thin-slice low-dose computed tomography in southwestern China: a population-based real-world study.Thorac Cancer. 2024 Jul;15(19):1522-1532. doi: 10.1111/1759-7714.15383. Epub 2024 May 27. Thorac Cancer. 2024. PMID: 38798230 Free PMC article.
References
-
- Abayalath N et al (2021) Characterization of airborne PAHs and metals associated with PM10 fractions collected from an urban area of Sri Lanka and the impact on airway epithelial cells. Chemosphere 286:131741. 10.1016/j.chemosphere.2021.131741 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous